Severe asthma is a difficult to treat disease, characterized by bronchial remodelling, which
is an abnormal repair process that contributes to the development of poorly reversible airway
narrowing. Such remodelling is now considered as one of the main prognostic factors.
Gallopamil-sensitive calcium influx plays a key role in this remodelling process in vitro.
The objective of this study is to compare the effects of gallopamil versus placebo on the
bronchial smooth muscle remodelling in severe asthmatic patients.